Efficacy and safety of retreatment with Elbasvir/Grazoprevir associated to Sofosbuvir plus /- Ribavirin in HCV infected patients with a previous failure to therapy with direct-acting antiviral drugs

被引：0
|
作者：
Alric, Laurent [1 ]
Leroy, Vincent [2 ]
Cotte, Laurent [3 ]
Anne, Minello [4 ]
Remy, Andre Jean [5 ]
Rouanet, Isabelle [6 ]
Godart, Marion [1 ]
Hezode, Christophe [7 ]
Abravanel, Florence [8 ]
Ollivier-Hourmand, Isabelle [9 ]
机构：
[1] CHU Purpan, Internal Med Digest Dept, Toulouse, France
[2] CHU, Digest Dept, Grenoble, France
[3] Hop Lyon, Digest Dept, Lyon, France
[4] CHU, Digest Dept, Dijon, France
[5] Hop Perpignan, Digest Dept, Perpignan, France
[6] CHU, Digest Dept, Nimes, France
[7] CHU Henri Mondor, Digest Dept, Creteil, France
[8] CHU Purpan, Virol, Toulouse, France
[9] CHU, Digest Dept, Caen, France
来源：
HEPATOLOGY | 2017年 / 66卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
1544
引用
收藏
页码：824A / 825A
页数：2
相关论文
共 50 条
  • [41] Real-world experience with direct-acting antiviral therapy in HCV-infected patients with cirrhosis and esophageal varices
    Brzdek, Michal
    Zarebska-Michaluk, Dorota
    Kukla, Michal
    Janocha-Litwin, Justyna
    Dybowska, Dorota
    Janczewska, Ewa
    Lorenc, Beata
    Berak, Hanna
    Mazur, Wlodzimierz
    Tudrujek-Zdunek, Magdalena
    Klapaczynski, Jakub
    Piekarska, Anna
    Sitko, Marek
    Laurans, Lukasz
    Parfieniuk-Kowerda, Anna
    Flisiak, Robert
    PHARMACOLOGICAL REPORTS, 2024, 76 (05) : 1114 - 1129
  • [42] MODELING THE COST-EFFECTIVENESS OF THE ALL ORAL, DIRECT-ACTING ANTIVIRAL REGIMEN DACLATASVIR PLUS SOFOSBUVIR IN PATIENTS CO-INFECTED WITH HEPATITIS C VIRUS (HCV) AND HIV
    McEwan, P.
    Ward, T.
    Webster, S.
    Kalsekar, A.
    Brenner, M.
    Yuan, Y.
    VALUE IN HEALTH, 2015, 18 (07) : A628 - A628
  • [43] Efficacy and safety of direct-acting antiviral regimens in HIV/HCV-co-infected patients - French ANRS CO13 HEPAVIH cohort
    Piroth, Lionel
    Wittkop, Linda
    Lacombe, Karine
    Rosenthal, Eric
    Gilbert, Camille
    Miailhes, Patrick
    Carrieri, Patrizia
    Chas, Julie
    Poizot-Martin, Isabelle
    Gervais, Anne
    Dominguez, Stephanie
    Neau, Didier
    Zucman, David
    Billaud, Eric
    Morlat, Philippe
    Aumaitre, Hugues
    Lascoux-Combe, Caroline
    Simon, Anne
    Bouchaud, Olivier
    Teicher, Elina
    Bani-Sadr, Firouze
    Alric, Laurent
    Vittecoq, Daniel
    Boue, Francois
    Duvivier, Claudine
    Valantin, Marc-Antoine
    Esterle, Laure
    Dabis, Francois
    Sogni, Philippe
    Salmon, Dominique
    JOURNAL OF HEPATOLOGY, 2017, 67 (01) : 23 - 31
  • [44] Retreatment of patients with chronic hepatitis C, subtype 1b and cirrhosis, who failed previous direct-acting antiviral therapy including first- and second-generation NS5A inhibitors with ombitasvir/paritaprevir/ritonavir, dasabuvir plus sofosbuvir plus ribavirin
    Fedorchenko, Sergii V.
    Martynovych, Tatiana
    Klimenko, Zhanna
    Yanchenko, Vitaliy
    Solianyk, Iryna
    JOURNAL OF VIRAL HEPATITIS, 2020, 27 (05) : 548 - 551
  • [45] A systematic review with meta-analysis: Is ribavirin necessary in sofosbuvir-based direct-acting antiviral therapies for patients with HCV recurrence after liver transplantation?
    Xue, Wei
    Liu, Kai
    Qiu, Ke
    Shen, Yanxi
    Pan, Zhaojun
    Hu, Peng
    Peng, Mingli
    Chen, Min
    Ren, Hong
    INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 2019, 83 : 56 - 63
  • [46] Real-world efficacy of glecaprevir plus pibrentasvir for chronic hepatitis C patient with previous direct-acting antiviral therapy failures
    Osawa, Mitsutaka
    Imamura, Michio
    Teraoka, Yuji
    Uchida, Takuro
    Morio, Kei
    Fujino, Hatsue
    Nakahara, Takashi
    Ono, Atsushi
    Murakami, Eisuke
    Kawaoka, Tomokazu
    Miki, Daiki
    Tsuge, Masataka
    Hiramatsu, Akira
    Aikata, Hiroshi
    Hayes, C. Nelson
    Chayama, Kazuaki
    Aimitsu, Shiomi
    Azakami, Takahiro
    Kamada, Koji
    Katamura, Yoshio
    Kawakami, Hiroiku
    Kawakami, Yoshiiku
    Kimura, Takashi
    Takahashi, Shoichi
    Tsuji, Keiji
    Takaki, Shintaro
    Mori, Nami
    Nagaoki, Yuko
    Moriya, Takashi
    Yamaguchi, Shuji
    JOURNAL OF GASTROENTEROLOGY, 2019, 54 (03) : 291 - 296
  • [47] Real-world efficacy of glecaprevir plus pibrentasvir for chronic hepatitis C patient with previous direct-acting antiviral therapy failures
    Mitsutaka Osawa
    Michio Imamura
    Yuji Teraoka
    Takuro Uchida
    Kei Morio
    Hatsue Fujino
    Takashi Nakahara
    Atsushi Ono
    Eisuke Murakami
    Tomokazu Kawaoka
    Daiki Miki
    Masataka Tsuge
    Akira Hiramatsu
    Hiroshi Aikata
    C. Nelson Hayes
    Kazuaki Chayama
    Journal of Gastroenterology, 2019, 54 : 291 - 296
  • [48] Successful treatment of hepatitis C genotype 4 using sofosbuvir, daclatasvir, simeprevir and ribavirin in Egyptian patients with direct-acting antiviral agent treatment failure
    Mohamed, Hala
    Abd El Ghany, Weal
    Yehia, Reem
    Fouad, Magdy
    CLINICAL AND EXPERIMENTAL HEPATOLOGY, 2022, 8 (01) : 36 - 41
  • [49] Direct-acting antiviral treatment of chronic HCV-infected patients on opioid substitution therapy: Still a concern in clinical practice?
    Christensen, Stefan
    Buggisch, Peter
    Mauss, Stefan
    Boker, Klaus H. W.
    Schott, Eckart
    Klinker, Hartwig
    Zimmermann, Tim
    Weber, Bernd
    Reimer, Jens
    Serfert, Yvonne
    Wedemeyer, Heiner
    ADDICTION, 2018, 113 (05) : 868 - 882
  • [50] Pangenotypic triple versus double therapy in HCV-infected patients after prior failure of direct-acting antivirals
    Flisiak, Robert
    Zarebska-Michaluk, Dorota
    Berak, Hanna
    Dybowska, Dorota
    Sitko, Marek
    Parfieniuk-Kowerda, Anna
    Janocha-Litwin, Justyna
    Janczewska, Ewa
    Piekarska, Anna
    Lorenc, Beata
    Mazur, Wlodzimierz
    Dobrowolska, Krystyna
    Tudrujek-Zdunek, Magdalena
    Klapaczynski, Jakub
    Jaroszewicz, Jerzy
    CLINICAL AND EXPERIMENTAL HEPATOLOGY, 2023, 9 (03) : 193 - 201
12345